HU203564B - Process for producing new orthorombos cyclosporin without solvatation - Google Patents

Process for producing new orthorombos cyclosporin without solvatation Download PDF

Info

Publication number: HU203564B
Authority: HU; Hungary
Prior art keywords: cyclosporin; orthorhombic; treatment; polyethylene glycol; particle size
Prior art date: 1987-12-21

Application number

HU886374A

Other languages

English (en)

Hungarian (hu)

Other versions

HUT49893A (en

Inventor

Danielle Giron

Martin List

Friedrich Richter

Yasuyuki Uike

Hans Peter Weber

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-12-21

Filing date

1988-12-09

Publication date

1991-08-28

1988-12-09 Application filed by Sandoz Ag filed Critical Sandoz Ag

1989-11-28 Publication of HUT49893A publication Critical patent/HUT49893A/hu

1991-08-28 Publication of HU203564B publication Critical patent/HU203564B/hu

Links

PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 140
108010036949 Cyclosporine Proteins 0.000 title claims abstract description 139
229960001265 ciclosporin Drugs 0.000 title claims abstract description 139
238000000034 method Methods 0.000 title claims abstract description 36
230000008569 process Effects 0.000 title claims abstract description 18
229930182912 cyclosporin Natural products 0.000 title claims description 105
229930105110 Cyclosporin A Natural products 0.000 title claims description 90
239000013078 crystal Substances 0.000 claims abstract description 36
239000012453 solvate Substances 0.000 claims abstract description 6
238000002360 preparation method Methods 0.000 claims description 34
-1 polyoxyethylene Polymers 0.000 claims description 30
229920001223 polyethylene glycol Polymers 0.000 claims description 23
239000002904 solvent Substances 0.000 claims description 16
239000002202 Polyethylene glycol Substances 0.000 claims description 15
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 13
239000003921 oil Substances 0.000 claims description 10
239000004094 surface-active agent Substances 0.000 claims description 10
235000014113 dietary fatty acids Nutrition 0.000 claims description 9
239000000194 fatty acid Substances 0.000 claims description 9
229930195729 fatty acid Natural products 0.000 claims description 9
229920000136 polysorbate Polymers 0.000 claims description 8
229920001451 polypropylene glycol Polymers 0.000 claims description 6
238000002441 X-ray diffraction Methods 0.000 claims description 5
150000003626 triacylglycerols Chemical class 0.000 claims description 5
150000002148 esters Chemical class 0.000 claims description 4
238000010586 diagram Methods 0.000 claims description 3
230000000699 topical effect Effects 0.000 abstract description 27
238000002347 injection Methods 0.000 abstract description 19
239000007924 injection Substances 0.000 abstract description 19
239000004480 active ingredient Substances 0.000 abstract description 8
230000002500 effect on skin Effects 0.000 abstract description 6
238000004519 manufacturing process Methods 0.000 abstract description 2
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 description 101
238000011282 treatment Methods 0.000 description 52
239000002245 particle Substances 0.000 description 49
238000009472 formulation Methods 0.000 description 42
239000000047 product Substances 0.000 description 33
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
201000004681 Psoriasis Diseases 0.000 description 27
206010052428 Wound Diseases 0.000 description 19
208000027418 Wounds and injury Diseases 0.000 description 19
239000000902 placebo Substances 0.000 description 19
229940068196 placebo Drugs 0.000 description 19
201000010099 disease Diseases 0.000 description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
239000000499 gel Substances 0.000 description 18
238000012360 testing method Methods 0.000 description 15
238000009826 distribution Methods 0.000 description 13
230000000144 pharmacologic effect Effects 0.000 description 12
239000006071 cream Substances 0.000 description 11
239000007788 liquid Substances 0.000 description 11
239000000243 solution Substances 0.000 description 11
238000002425 crystallisation Methods 0.000 description 10
230000008025 crystallization Effects 0.000 description 10
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 10
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 10
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
239000010419 fine particle Substances 0.000 description 9
208000003251 Pruritus Diseases 0.000 description 8
206010046851 Uveitis Diseases 0.000 description 8
239000000969 carrier Substances 0.000 description 8
230000000694 effects Effects 0.000 description 8
230000006872 improvement Effects 0.000 description 8
229940068886 polyethylene glycol 300 Drugs 0.000 description 8
208000017520 skin disease Diseases 0.000 description 8
239000003814 drug Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 7
229920000159 gelatin Polymers 0.000 description 7
235000019322 gelatine Nutrition 0.000 description 7
239000002674 ointment Substances 0.000 description 7
235000019271 petrolatum Nutrition 0.000 description 7
238000003756 stirring Methods 0.000 description 7
239000000725 suspension Substances 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
108010010803 Gelatin Proteins 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
230000001363 autoimmune Effects 0.000 description 6
230000036576 dermal application Effects 0.000 description 6
235000011852 gelatine desserts Nutrition 0.000 description 6
239000000463 material Substances 0.000 description 6
239000013081 microcrystal Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
238000007127 saponification reaction Methods 0.000 description 6
239000003381 stabilizer Substances 0.000 description 6
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 5
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
206010003645 Atopy Diseases 0.000 description 5
201000004624 Dermatitis Diseases 0.000 description 5
206010012442 Dermatitis contact Diseases 0.000 description 5
206010048768 Dermatosis Diseases 0.000 description 5
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
239000004599 antimicrobial Substances 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
239000011630 iodine Substances 0.000 description 5
229910052740 iodine Inorganic materials 0.000 description 5
230000007803 itching Effects 0.000 description 5
238000002844 melting Methods 0.000 description 5
230000008018 melting Effects 0.000 description 5
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 5
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 5
229960002216 methylparaben Drugs 0.000 description 5
230000006911 nucleation Effects 0.000 description 5
238000010899 nucleation Methods 0.000 description 5
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
229920000053 polysorbate 80 Polymers 0.000 description 5
LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 4
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical class CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
201000004384 Alopecia Diseases 0.000 description 4
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
229920001214 Polysorbate 60 Polymers 0.000 description 4
239000002253 acid Substances 0.000 description 4
206010003246 arthritis Diseases 0.000 description 4
239000004359 castor oil Substances 0.000 description 4
235000019438 castor oil Nutrition 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
238000004090 dissolution Methods 0.000 description 4
239000003995 emulsifying agent Substances 0.000 description 4
150000002170 ethers Chemical class 0.000 description 4
208000030533 eye disease Diseases 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
239000008187 granular material Substances 0.000 description 4
238000000265 homogenisation Methods 0.000 description 4
206010023332 keratitis Diseases 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
239000004006 olive oil Substances 0.000 description 4
239000006186 oral dosage form Substances 0.000 description 4
229940100688 oral solution Drugs 0.000 description 4
239000008389 polyethoxylated castor oil Substances 0.000 description 4
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 4
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 4
229960003415 propylparaben Drugs 0.000 description 4
230000009467 reduction Effects 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
230000008719 thickening Effects 0.000 description 4
235000015112 vegetable and seed oil Nutrition 0.000 description 4
239000008158 vegetable oil Substances 0.000 description 4
239000003871 white petrolatum Substances 0.000 description 4
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
208000023275 Autoimmune disease Diseases 0.000 description 3
206010010741 Conjunctivitis Diseases 0.000 description 3
206010012438 Dermatitis atopic Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
235000019483 Peanut oil Nutrition 0.000 description 3
239000004698 Polyethylene Substances 0.000 description 3
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229920002125 Sokalan® Polymers 0.000 description 3
201000008937 atopic dermatitis Diseases 0.000 description 3
235000019445 benzyl alcohol Nutrition 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
230000008859 change Effects 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
208000010247 contact dermatitis Diseases 0.000 description 3
RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
239000003925 fat Substances 0.000 description 3
239000000945 filler Substances 0.000 description 3
239000008394 flocculating agent Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
238000000227 grinding Methods 0.000 description 3
239000003018 immunosuppressive agent Substances 0.000 description 3
229940125721 immunosuppressive agent Drugs 0.000 description 3
238000001802 infusion Methods 0.000 description 3
239000007972 injectable composition Substances 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 3
239000000312 peanut oil Substances 0.000 description 3
230000000704 physical effect Effects 0.000 description 3
229920001281 polyalkylene Polymers 0.000 description 3
229920005862 polyol Polymers 0.000 description 3
150000003077 polyols Chemical class 0.000 description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
230000001185 psoriatic effect Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000012049 topical pharmaceutical composition Substances 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
235000019489 Almond oil Nutrition 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
208000012659 Joint disease Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
235000019482 Palm oil Nutrition 0.000 description 2
239000004264 Petrolatum Substances 0.000 description 2
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
206010053262 Skin swelling Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
208000002029 allergic contact dermatitis Diseases 0.000 description 2
239000008168 almond oil Substances 0.000 description 2
231100000360 alopecia Toxicity 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
206010008129 cerebral palsy Diseases 0.000 description 2
238000000576 coating method Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000002285 corn oil Substances 0.000 description 2
235000005687 corn oil Nutrition 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
235000013365 dairy product Nutrition 0.000 description 2
230000009977 dual effect Effects 0.000 description 2
229960003276 erythromycin Drugs 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
230000001815 facial effect Effects 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
230000002538 fungal effect Effects 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
208000024963 hair loss Diseases 0.000 description 2
230000003676 hair loss Effects 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
239000012051 hydrophobic carrier Substances 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000002650 immunosuppressive therapy Methods 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
238000009533 lab test Methods 0.000 description 2
229940057995 liquid paraffin Drugs 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
239000002540 palm oil Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000006072 paste Substances 0.000 description 2
230000001175 peptic effect Effects 0.000 description 2
229940066842 petrolatum Drugs 0.000 description 2
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
229920001515 polyalkylene glycol Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229940068965 polysorbates Drugs 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
235000011069 sorbitan monooleate Nutrition 0.000 description 2
239000001593 sorbitan monooleate Substances 0.000 description 2
229940035049 sorbitan monooleate Drugs 0.000 description 2
239000001384 succinic acid Substances 0.000 description 2
230000035900 sweating Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
238000005809 transesterification reaction Methods 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
238000005406 washing Methods 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 1
FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 1
JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 description 1
206010007764 Cataract subcapsular Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010011017 Corneal graft rejection Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
229910016523 CuKa Inorganic materials 0.000 description 1
208000001840 Dandruff Diseases 0.000 description 1
208000003556 Dry Eye Syndromes Diseases 0.000 description 1
206010013774 Dry eye Diseases 0.000 description 1
SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
206010016825 Flushing Diseases 0.000 description 1
206010061958 Food Intolerance Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000023661 Haematological disease Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
201000002287 Keratoconus Diseases 0.000 description 1
208000001126 Keratosis Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
206010023799 Large intestinal ulcer Diseases 0.000 description 1
229920003102 Methocel™ E4M Polymers 0.000 description 1
ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
108010002885 Polygeline Proteins 0.000 description 1
229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229920001219 Polysorbate 40 Polymers 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920001304 Solutol HS 15 Polymers 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
235000019498 Walnut oil Nutrition 0.000 description 1
208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
206010048222 Xerosis Diseases 0.000 description 1
IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000009285 allergic inflammation Effects 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
238000011861 anti-inflammatory therapy Methods 0.000 description 1
230000000078 anti-malarial effect Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
239000003904 antiprotozoal agent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000011948 assay development Methods 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
229960000623 carbamazepine Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
229940074979 cetyl palmitate Drugs 0.000 description 1
208000007287 cheilitis Diseases 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
238000012864 cross contamination Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
108010019249 cyclosporin G Proteins 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
201000002545 drug psychosis Diseases 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
229920000591 gum Polymers 0.000 description 1
230000003779 hair growth Effects 0.000 description 1
238000013038 hand mixing Methods 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
206010021198 ichthyosis Diseases 0.000 description 1
208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
239000007942 layered tablet Substances 0.000 description 1
239000004571 lime Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
230000003387 muscular Effects 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
231100000381 nephrotoxic Toxicity 0.000 description 1
210000002445 nipple Anatomy 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
238000002103 osmometry Methods 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000003209 petroleum derivative Substances 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000019612 pigmentation Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000009597 pregnancy test Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229940024473 salicylic acid emollient and protective preparations Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000005549 size reduction Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229940046303 sodium cetostearyl sulfate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
229940084026 sodium valproate Drugs 0.000 description 1
CLBALUNQCMWJSU-UHFFFAOYSA-L sodium;hexadecyl sulfate;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O CLBALUNQCMWJSU-UHFFFAOYSA-L 0.000 description 1
238000000527 sonication Methods 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
235000011078 sorbitan tristearate Nutrition 0.000 description 1
239000001589 sorbitan tristearate Substances 0.000 description 1
229960004129 sorbitan tristearate Drugs 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000006257 total synthesis reaction Methods 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
229940099259 vaseline Drugs 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000008170 walnut oil Substances 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
230000037303 wrinkles Effects 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Transplantation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

HU886374A 1987-12-21 1988-12-09 Process for producing new orthorombos cyclosporin without solvatation HU203564B (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US13623087A	1987-12-21	1987-12-21
US17261388A	1988-03-24	1988-03-24
US21254888A	1988-06-28	1988-06-28

Publications (2)

Publication Number	Publication Date
HUT49893A HUT49893A (en)	1989-11-28
HU203564B true HU203564B (en)	1991-08-28

Family

ID=27384838

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU886374A HU203564B (en)	1987-12-21	1988-12-09	Process for producing new orthorombos cyclosporin without solvatation

Country Status (27)

Country	Link
JP (1)	JPH0791316B2 (fr)
KR (1)	KR100188305B1 (fr)
AT (1)	AT403163B (fr)
AU (1)	AU626274B2 (fr)
BE (1)	BE1002665A4 (fr)
CA (1)	CA1341396C (fr)
CH (1)	CH677926A5 (fr)
CY (1)	CY1799A (fr)
DE (1)	DE3843054C2 (fr)
DK (1)	DK175220B1 (fr)
ES (1)	ES2012580A6 (fr)
FI (1)	FI89065C (fr)
FR (1)	FR2624863B1 (fr)
GB (1)	GB2211848B (fr)
GR (1)	GR1002486B (fr)
HK (1)	HK102894A (fr)
HU (1)	HU203564B (fr)
IE (1)	IE62006B1 (fr)
IL (1)	IL88719A0 (fr)
IT (1)	IT1235356B (fr)
LU (1)	LU87409A1 (fr)
MY (1)	MY103943A (fr)
NL (1)	NL195096C (fr)
NO (1)	NO177228C (fr)
NZ (1)	NZ227384A (fr)
SE (1)	SE503174C2 (fr)
SG (1)	SG99494G (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5639724A (en)	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
GB2222770B (en) *	1988-09-16	1992-07-29	Sandoz Ltd	Pharmaceutical compositions containing cyclosporins
US6007840A (en) *	1988-09-16	1999-12-28	Novartis Ag	Pharmaceutical compositions comprising cyclosporins
US7081445B2 (en)	1989-02-20	2006-07-25	Novartis Ag	Cyclosporin galenic forms
US5294604A (en) *	1989-12-20	1994-03-15	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating ocular diseases by periocular administration of cyclosporine A or G
GB9105705D0 (en) *	1991-03-18	1991-05-01	Sandoz Ltd	Improvements in or relating to organic compounds
US6262022B1 (en)	1992-06-25	2001-07-17	Novartis Ag	Pharmaceutical compositions containing cyclosporin as the active agent
DE69307505T2 (de) *	1992-05-13	1997-07-24	Sandoz-Patent-Gmbh, 79539 Loerrach	Opthalmische zusammensetzungen enthaltend ein cyclosporin
EP1142568A1 (fr)	1992-09-25	2001-10-10	Novartis AG	Compositions pharmaceutiques à base de cyclosporines
AU715165B2 (en)	1994-11-03	2000-01-20	Novartis Ag	Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability, and process for producing them
US5766629A (en)	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
US5962019A (en) *	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
DE19544507B4 (de)	1995-11-29	2007-11-15	Novartis Ag	Cyclosporin enthaltende Präparate
US6262054B1 (en)	1996-02-01	2001-07-17	Sloan-Kettering Institute Of Cancer Research	Combination therapy method for treating breast cancer using edatrexate
EP1331002A3 (fr)	1997-01-30	2004-01-14	Novartis AG	Compositions pharmaceutiques exemptes d'huile, à base de cyclosporine A
TW581681B (en)	1998-02-20	2004-04-01	Nektar Therapeutics	Liquid crystal forms of cyclosporin
US7732404B2 (en)	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin
EP1706095B1 (fr)	2004-01-20	2008-12-24	Allergan, Inc.	Compositions pour therapie localisee de l'oeil, de preference a base de triamcinolone acetonide et d'acide hyaluronique
CN1763084B (zh) *	2005-10-11	2010-04-21	山东新时代药业有限公司	高纯度环孢菌素a的制备方法
CA2836946C (fr)	2011-05-27	2017-08-01	Allergan, Inc.	Forme cristalline de cyclosporine a, procedes de preparation et procedes d'utilisation associes
RU2630970C2 (ru) *	2011-11-15	2017-09-15	Аллерган, Инк.	Автоклавируемые взвеси циклоспорина а формы 2
ES2666191T3 (es) *	2011-11-15	2018-05-03	Allergan, Inc.	Un proceso para la cristalización de la forma 2 de la ciclosporina A
RU2639393C2 (ru)	2011-11-15	2017-12-21	Аллерган, Инк.	Состав пролонгированного действия циклоспорина формы 2
JP6363506B2 (ja)	2011-11-15	2018-07-25	アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ	シクロスポリンａ２型の懸濁剤
EP4585605A1 (fr) *	2022-10-20	2025-07-16	Chugai Seiyaku Kabushiki Kaisha	Procédé de production de cristaux peptidiques cycliques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH614931A5 (fr) *	1975-11-04	1979-12-28	Sandoz Ag
CH640519A5 (en) *	1976-04-09	1984-01-13	Sandoz Ag	Process for preparing a modified form of the antibiotic S 7481/F-1
US4117118A (en) *	1976-04-09	1978-09-26	Sandoz Ltd.	Organic compounds
DE2819094A1 (de) *	1977-05-10	1978-11-23	Sandoz Ag	Cyclosporin-derivate, ihre verwendung und herstellung
CH637124A5 (en) *	1978-10-18	1983-07-15	Sandoz Ag	Antibiotic, its preparation and use

1988
- 1988-12-09 HU HU886374A patent/HU203564B/hu unknown
- 1988-12-19 GB GB8829556A patent/GB2211848B/en not_active Expired - Lifetime
- 1988-12-19 CH CH4687/88A patent/CH677926A5/de not_active IP Right Cessation
- 1988-12-19 AU AU27055/88A patent/AU626274B2/en not_active Expired
- 1988-12-19 IL IL88719A patent/IL88719A0/xx unknown
- 1988-12-19 DK DK198807054A patent/DK175220B1/da not_active IP Right Cessation
- 1988-12-19 NZ NZ227384A patent/NZ227384A/xx unknown
- 1988-12-19 FI FI885869A patent/FI89065C/fi not_active IP Right Cessation
- 1988-12-19 NO NO885625A patent/NO177228C/no unknown
- 1988-12-19 FR FR888816886A patent/FR2624863B1/fr not_active Expired - Lifetime
- 1988-12-19 SE SE8804570A patent/SE503174C2/sv not_active IP Right Cessation
- 1988-12-19 IE IE377988A patent/IE62006B1/en not_active IP Right Cessation
- 1988-12-20 GR GR880100850A patent/GR1002486B/el not_active IP Right Cessation
- 1988-12-20 BE BE8801421A patent/BE1002665A4/fr not_active IP Right Cessation
- 1988-12-20 AT AT0309588A patent/AT403163B/de not_active IP Right Cessation
- 1988-12-20 JP JP63321857A patent/JPH0791316B2/ja not_active Expired - Lifetime
- 1988-12-20 IT IT8848690A patent/IT1235356B/it active
- 1988-12-20 KR KR1019880017194A patent/KR100188305B1/ko not_active Expired - Lifetime
- 1988-12-20 LU LU87409A patent/LU87409A1/fr unknown
- 1988-12-21 MY MYPI88001495A patent/MY103943A/en unknown
- 1988-12-21 CA CA000586611A patent/CA1341396C/fr not_active Expired - Fee Related
- 1988-12-21 NL NL8803125A patent/NL195096C/nl active Search and Examination
- 1988-12-21 DE DE3843054A patent/DE3843054C2/de not_active Expired - Lifetime
- 1988-12-21 ES ES8803887A patent/ES2012580A6/es not_active Expired - Lifetime
1994
- 1994-07-21 SG SG99494A patent/SG99494G/en unknown
- 1994-09-22 HK HK102894A patent/HK102894A/xx not_active IP Right Cessation
1995
- 1995-02-17 CY CY179995A patent/CY1799A/en unknown

Also Published As

Publication number	Publication date
IE883779L (en)	1989-06-21
GB2211848A (en)	1989-07-12
NZ227384A (en)	1991-09-25
IL88719A0 (en)	1989-07-31
NL8803125A (nl)	1989-07-17
IT1235356B (it)	1992-06-30
CH677926A5 (fr)	1991-07-15
SE8804570D0 (sv)	1988-12-19
MY103943A (en)	1993-10-30
NO177228B (no)	1995-05-02
ES2012580A6 (es)	1990-04-01
FR2624863A1 (fr)	1989-06-23
KR100188305B1 (ko)	1999-06-01
DE3843054A1 (de)	1989-07-27
CA1341396C (fr)	2002-11-05
HK102894A (en)	1994-09-30
JPH01211598A (ja)	1989-08-24
DK705488D0 (da)	1988-12-19
NL195096C (nl)	2004-02-09
HUT49893A (en)	1989-11-28
GB8829556D0 (en)	1989-02-08
KR890009975A (ko)	1989-08-05
DE3843054C2 (de)	2003-08-21
AU2705588A (en)	1989-06-22
GR1002486B (el)	1996-12-09
GB2211848B (en)	1991-11-06
JPH0791316B2 (ja)	1995-10-04
DK175220B1 (da)	2004-07-12
FI89065C (fi)	1993-09-30
FR2624863B1 (fr)	1991-04-26
AU626274B2 (en)	1992-07-30
NO885625L (no)	1989-06-22
BE1002665A4 (fr)	1991-04-30
IE62006B1 (en)	1994-12-14
SE8804570L (sv)	1989-06-22
FI885869L (fi)	1989-06-22
FI89065B (fi)	1993-04-30
GR880100850A (el)	1994-03-31
SE503174C2 (sv)	1996-04-15
SG99494G (en)	1994-10-28
CY1799A (en)	1995-02-17
NO177228C (no)	1995-08-09
ATA309588A (de)	1997-04-15
AT403163B (de)	1997-11-25
FI885869A0 (fi)	1988-12-19
LU87409A1 (fr)	1989-07-07
DK705488A (da)	1989-06-22
NO885625D0 (no)	1988-12-19
IT8848690A0 (it)	1988-12-20

Legal Events

Date	Code	Title	Description
1997-11-28	HPC4	Succession in title of patentee	Owner name: NOVARTIS AG, CH

Publication	Publication Date	Title
HU203564B (en)	1991-08-28	Process for producing new orthorombos cyclosporin without solvatation
AT404552B (de)	1998-12-28	Neue cyclosporin enthaltende galenische formulierungen
US5756450A (en)	1998-05-26	Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
EP3104844B1 (fr)	2020-02-12	Complexes de sirolimus et leur dérivés, leur procédé de préparation et compositions pharmaceutiques les contenant
HU211685A9 (en)	1995-12-28	Pharmaceutical compositions containing cyclosporins
HUT73664A (en)	1996-09-30	Pharmaceutically acceptable improved compositions containing an alcohol and a hydrophobic drug
HU205010B (en)	1992-03-30	Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity
JP2003510267A (ja)	2003-03-18	医薬担体処方
CN102309438A (zh)	2012-01-11	一种咪达唑仑药物组合物、其制备方法及用途
SK278320B6 (en)	1996-10-02	Process for producing of cyclosporine a
WO2001051089A1 (fr)	2001-07-19	Compositions pharmaceutiques contenant de la 2-pyrrolidone en tant qu'agent de solubilisation
JPH07291863A (ja)	1995-11-07	腎保護作用剤
HU212727B (en)	1996-10-28	Process for producing pharmaceutical compositions in form of microemulsion-prae-concentrate or microemulsion containing cyclosporin(s) as active component
WO2001051052A1 (fr)	2001-07-19	Composition pharmaceutique contenant des inhibiteurs de pde v specifiques